SkinBioTherapeutics PLC Notification of first patent grant (0661Y)
01 December 2017 - 6:05PM
UK Regulatory
TIDMSBTX
RNS Number : 0661Y
SkinBioTherapeutics PLC
30 November 2017
SkinBioTherapeutics plc
Notification of first patent grant
Manchester, UK - 1 December 2017 - SkinBioTherapeutics plc (AIM:
SBTX, the "Company"), a life science company focused on skin
health, announces the granting of the first patent for its
SkinBiotix(R) technology in Australia.
The patent granted covers the use of specific probiotic bacteria
and lysates in the treatment of skin in health and disease. This
marks the Company's first patent to progress to grant from within
its portfolio of patents pending estate. The patent, numbered
2013246701 and entitled 'Probiotic bacteria', runs until 15 March
2033.
The patent is in active prosecution in other locations worldwide
including Europe, USA and China.
Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:
"The Australian skincare market is a key global market. The
progression and successful grant of the first national patent to
emerge from the Company's Skinbiotix(R) patent family underpins the
commercial potential worldwide.
"This is a step forward in preparing for human trials, which are
scheduled for 2018."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
-Ends-
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161 468
Dr. Cath O'Neill, CEO 2760
Doug Quinn, CFO
Cairn Financial Advisers LLP Tel: +44 (0) 20 7213
Tony Rawlinson / Emma Earl / Richard 0880
Nash
Turner Pope Investments Tel: +44 (0) 20 3621
Ben Turner / James Pope 4120
Instinctif Partners Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Deborah Bell 2020
SkinBio@instinctif.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine
O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made
on the activities of lysates derived from probiotic bacteria when
applied to the skin. The Company has shown that the SkinBiotix(R)
platform can improve the barrier effect of skin models, protect
skin models from infection and repair skin models. Proof of
principle studies have shown that the SkinBiotix(R) platform has
beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer
office of the University of Manchester for the discovery of
SkinBiotix(R). The platform was subsequently spun out of the
University of Manchester in March 2016 and was funded by OptiBiotix
(AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising
GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information,
visit www.skinbiotherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESFDMFUSFWSEEF
(END) Dow Jones Newswires
December 01, 2017 02:05 ET (07:05 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024